XML 25 R8.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Net loss $ (141,901) $ (116,112) $ (75,617)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 288 215 158
Accretion and amortization on investments, net (965) 1,424 818
Amortization of debt issuance costs/debt discount 1,327 893 179
Gain on sales of available for sale securities     (19)
Net gain on exchange and sales of equity investment   (1,233) (148)
Change in fair value of equity investment, including foreign currency translation     (163)
Stock-based compensation for services by non-employees 264 91 85
Stock-based compensation for employees and directors 8,001 8,080 6,895
Amortization of right-of-use assets 580 568 777
Changes in assets and liabilities:      
Interest and other receivables (1,381) (1,041) 80
Prepaid and other current assets (2,630) 1,317 (1,286)
Deposit and other assets (594) (3,807) (206)
Accounts payable 3,503 (232) 5,731
Accrued compensation and benefits 3,435 (119) 3,388
Amount due to Janssen Biotech, Inc.     (14,269)
Accrued liabilities 3,266 14,909 7,397
Operating lease liabilities (572) (509) (452)
Net cash used in operating activities (127,379) (95,556) (66,652)
Cash flows from investing activities:      
Purchases of property and equipment (431) (207) (401)
Purchases of marketable securities (258,007) (177,434) (313,201)
Proceeds from sales of securities available for sale     7,681
Proceeds from maturities of marketable securities 320,505 247,994 200,262
Proceeds from sales of equity investment   1,594 339
Net cash provided by (used in) investing activities 62,067 71,947 (105,320)
Cash flows from financing activities:      
Proceeds from issuances of common stock from equity plans 2,185 797 208
Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs 69,916   140,184
Proceeds from issuances of common stock from at market offerings, net of paid issuance costs   20,385 4,075
Proceeds from exercise of warrants 15,163 2,479 16
Proceeds from debt financing, net of paid debt issuance costs and debt discounts   24,895 23,863
Net cash provided by financing activities 87,264 48,556 168,346
Net effect of unrealized gains and exchange rates on cash, cash equivalents and restricted cash 22    
Net increase (decrease) in cash, cash equivalents and restricted cash 21,974 24,947 (3,626)
Cash, cash equivalents and restricted cash at the beginning of the period 35,235 10,288 13,914
Cash, cash equivalents and restricted cash at the end of the period $ 57,209 $ 35,235 $ 10,288